Consulta: creatorFacets:"Tengan,Fátima Mitiko"
Registros recuperados: 2
Data/hora: 05/06/2024 16:01:40

Are anti-interferon antibodies the cause of failure in: chronic HCV hepatitis treatment?
Provedor de dados: 55
Autores: Barone,Antonio Alci; Tosta,Rose Aparecida Borges; Tengan,Fátima Mitiko; Marins,José Humberto Caetano; Cavalheiro,Norma de Paula; Cardi,Bruno Andrade.
A follow-up study was made of 94 chronic hepatitis C patients at a hepatitis clinic in Brazil, after interferon alpha (IFN-alpha) therapy, to determine the influence of anti-interferon antibodies on treatment outcome. Patients diagnosed as having chronic hepatitis C, confirmed by PCR (HCV RNA) and liver biopsy, were treated with interferon alpha 2a or 2b for at least six months, and were followed up for 24 weeks after termination of treatment in order to assess biochemical, virological and clinical pathology responses. Only 6% of the 94 patients developed anti-IFN antibodies, 70% presented a biochemical response and 23% maintained a sustained virological response. Clinical evaluation revealed that in only 2 patients was there progression of fibrosis; the...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Interferon-alpha; Antibodies; Chronic HCV; Treatment.
Ano: 2004
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000100002

Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment
Provedor de dados: 55
Autores: Cavalheiro,Norma de Paula; Filgueiras,Thelma Cristina; Melo,Carlos Eduardo; Morimitsu,Suzana Rie; Araújo,Evaldo Stanislau Affonso de; Tengan,Fátima Mitiko; Barone,Antonio Alci.
Although hepatitis C is mainly hepatotropic, some studies suggest that hepatitis C virus (HCV) infects peripheral blood mononuclear cells (PBMC), using them as a reservoir, which might contribute to the development of resistance to treatment. Fifty-four hepatitis-C patients, who had been submitted to treatment, were selected. Blood samples were collected on the same day for the detection of HCV RNA in serum and PBMC by PCR, using the Amplicor HCV 2.0 assay (Roche Diagnostics). HCV genotyping was performed using the INNO-LiPA HCV kit (Versant, Bayer Diagnostics). HCV RNA was detected in both serum and PBMC in 35 (64%) patients and no RNA in 16 (29.6%). Disagreement between the serum and PBMC results was observed for three patients (5.6%), with HCV RNA being...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: PCR; Hepatitis C; PBMC; Treatment.
Ano: 2007
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000500006